Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin, 300070, China.
Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin, 300070, China.
Comput Biol Chem. 2019 Feb;78:133-143. doi: 10.1016/j.compbiolchem.2018.10.013. Epub 2018 Oct 29.
Juvenile myelomonocytic leukaemia, an aggressive myeloproliferative neoplasm, is characterized by thrombocytopenia, splenomegaly, fever and excess myelomonocytic cells. Approximately 35% of patients with JMML occur D61Y mutation in PTPN11, and it increases the activity of the protein. However, the effect of the D61Y mutation on SHP2 conformations in molecular basis is poorly understood. Therefore, the molecular dynamics simulations on SHP2-D61Y and SHP2-WT were performed to explore the effect of D61Y mutation on SHP2 and explain the reason for high activity of SHP2-D61Y mutant. The study on the RMSF, per-residue RMSD, PCA, DCCM and secondary structure found that the flexibilities of regions (residues His458-Ser460 and Gln506-Ala509) in SHP2-D61Y were higher than the corresponding regions in SHP2-WT, and the conformations of these regions almost transformed from α-helix and β-strand to Turn, respectively. Thus, the catalytical sites in the PTP domain (residues Asn217-Thr524) were exposed to the substrate easily, which contributed to the enhancement of SHP2-D61Y activity. Moreover, the residue interaction network, H bond occupancy and binding free energy were calculated, revealing that conformational difference were caused by distinctions in residue-residue interactions between Asp/Tyr61-Gln506, Gln506-Gln510, Gln506-Phe251, Gln506-Gly60, Gln506-Tyr63, Asp/Tyr61-Cys459, Cys459-Ile463 and Cys459-Arg465. The study here may offer the valuable information to explore the reason for the increased activity of SHP2 after D61Y-mutation.
青少年骨髓单核细胞白血病是一种侵袭性骨髓增殖性肿瘤,其特征为血小板减少、脾肿大、发热和过多的骨髓单核细胞。大约 35%的 JMML 患者发生 PTPN11 中的 D61Y 突变,从而增加了该蛋白的活性。然而,D61Y 突变对 SHP2 构象的分子基础的影响尚不清楚。因此,对 SHP2-D61Y 和 SHP2-WT 进行了分子动力学模拟,以研究 D61Y 突变对 SHP2 的影响,并解释 SHP2-D61Y 突变体高活性的原因。通过 RMSF、残基 RMSD、PCA、DCCM 和二级结构的研究发现,SHP2-D61Y 中区域(残基 His458-Ser460 和 Gln506-Ala509)的柔韧性高于 SHP2-WT 中的相应区域,这些区域的构象几乎从α-螺旋和β-折叠分别转变为转角。因此,PTP 结构域(残基 Asn217-Thr524)中的催化位点很容易暴露于底物,这有助于增强 SHP2-D61Y 的活性。此外,还计算了残基相互作用网络、氢键占有率和结合自由能,表明构象差异是由 Asp/Tyr61-Gln506、Gln506-Gln510、Gln506-Phe251、Gln506-Gly60、Gln506-Tyr63、Asp/Tyr61-Cys459、Cys459-Ile463 和 Cys459-Arg465 残基之间的残基相互作用差异引起的。本研究可为探索 D61Y 突变后 SHP2 活性增加的原因提供有价值的信息。